Mirtazapine versus other anti-depressive agents for depression
Citation: Watanabe N., Omori I.M., Nakagaw A., et al. Mirtazapine versus other anti-depressive agents for depression. Cochrane Database of Systematic Reviews 2011, Issue 12. Art. No.: CD006528. DOI: 10.1002/14651858.CD006528.pub2
Mirtazapine is likely to have a faster onset of action than SSRIs during the acute‐phase treatment for depression over a 6-12-week period.
Depression is characterised by a persistent low mood, loss of interest and pleasure, loss of appetite, insomnia, fatigue, poor concentration and even suicide. Anti-depressants, including mirtazapine which has a unique pharmacological profile, are the mainstay of treatment for major depression. The aim of this review was to assess the efficacy and acceptability of mirtazapine compared with other anti-depressants in the acute‐phase treatment of major depression in adults. This review included findings from 29 randomised controlled trials (4974 participants in total) and concluded that mirtazapine is likely to have a faster onset of action than selective serotonin reuptake inhibitors (SSRIs). However, mirtazapine causes adverse events that lead to a similar frequency of dropouts as SSRIs and tricyclic antidepressants. It is likely to cause weight gain or increased appetite and somnolence but is less likely to cause nausea or vomiting and sexual dysfunction than SSRIs.
Disclaimer: This summary has been written by staff and volunteers of Evidence Aid in order to make the content of the original document accessible to decision makers who are searching for the available evidence on the health of refugees and asylum seekers but may not have the time, initially, to read the original report in full. This summary is not intended as a substitute for the medical advice of physicians, other health workers, professional associations, guideline developers, or national governments and international agencies. If readers of this summary think that the evidence that is presented within it is relevant to their decision-making they should refer to the content and details of the original article, and the advice and guidelines offered by other sources of expertise, before making decisions. Evidence Aid cannot be held responsible for any decisions made about the health of refugees and asylum seekers on the basis of this summary alone.
If you have found this summary helpful, please consider making a donation. If everyone who looked at our COVID-19 resources gave us just £2 per month, it would fund Evidence Aid’s life-saving work.